Quince Therapeutics Presents Preclinical Data at MHSRS 2022 Demonstrating Preclinical Efficacy of Bone-targeting Platform for Traumatic Bone Injury
MHSRS 2002 Poster Highlights
The following are highlights from the company’s poster presentation of preclinical data of NOV004 at MHSRS 2022:
Poster: Engineered Bone Fracture Targeted Parathyroid Hormone Agonist as an Effective Pharmaceutical for Accelerated Bone Repair in Mouse and Canine Models
Each year in the
U.S., there are more than 18 million fractures leading to more than $50 billionin direct medical costs. NOV004 is a fracture-targeted bone anabolic agent that concentrates selectively on the bone fracture surface and induces accelerated bone formation only at the damaged site.
- Quince believes that the systemic administration of NOV004 could provide a potential opportunity to treat stress fractures, multisite trauma, as well as operative and nonoperative fractures. There are currently no FDA approved systemic therapies for fracture repair.
- In preclinical studies, Quince observed a decrease in fracture healing time by 50% in NOV004 treated groups. Additionally, bone deposition and max load doubled and the force required to refracture the bones increased more than two-fold in mouse models.
To view the poster presented at MHSRS 2022, please visit the Science section of Quince’s corporate website.
Statements in this news release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this news release may be identified by the use of words such as “anticipate,” “expect,” “will,” “can,” “may,” “should,” “estimate,” “project,” “potential,” “encouraged,” “positioned,” or other similar words. Examples of forward-looking statements include, among others, the clinical development and strategic development path for NOV004; the timing and success of the company’s clinical trials and related data, including plans and the ability to initiate, conduct and/or complete the Phase 1 clinical studies for NOV004; the potential therapeutic benefits, safety, and efficacy of the company’s bone-targeting platform, product candidate and discovery pipeline. Forward-looking statements are based on Quince Therapeutics’ current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in the company’s Annual Report on Form 10-K filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20220916005037/en/
Quince Therapeutics Contact: